erosols are particles suspended in a gaseous medium that may be inhaled and, depending on their physical properties, the specific parameters of For editorial comment see page 336 ventilation, and airway geometry, will deposit to varying degrees throughout the respiratory tract.1 Aerosols account for the spread of certain infectious lung diseases, as well as exposure to noxious agents resulting in interstitial lung disease and even malignancy.
Aerosols have been employed as a means of drug delivery in the treatment of respiratory disorders. The theoretical advantages of drug administration by inhaled aerosol include delivery of drugs that might not be active via other routes and local delivery of drug in large doses so as to maximize effect and minimize systemic toxic reactions. The details of drug delivery and kinetics must be determined if an agent is to be administered in a rational and predictable fashion. Most of the clinical data supporting the use of aerosol therapies have been derived from study of nonintubated patients, during treatment of airflow obstruction with bronchodilators or anti-inflammatory drugs. Nevertheless, bronchodilators are used frequently in intubated patients undergoing mechanical ventilation, and innovative therapies, including aerosolized surfactant and antibiotics, have also been administered to critically ill patients. There are a number of reasons why simple adaptation of techniques effective in administering drugs in the nonintubated patient may not be equally effective during mechanical ventilation. These include the following: (1) airway mucosal function and hence drug absorption may be altered during critical illness; (2) the endotracheal tube and ventilator circuit may trap aerosolized drug before it reaches the patient's airway or may alter aerosol distribution within the respiratory tract; (3) FIGURE 1 . Design of the earliest therapeutic aerosol device-the nebulizer squeeze bottle. By squeezing the rubber bulb, flow is channelled above the fluid phase reservoir creating a pressure differential that causes aerosolization and entrainment in the gas flow toward the patient.
first, the hand-held squeeze-bulb nebulizer, used a rubber bulb attached to a thin hollow cylinder above a reservoir of liquid. By squeezing the bulb, a flow of air is created that creates a Bernoulli effect in the cylinder. Since the cylinder is open to the liquid phase reservoir, a pressure gradient develops between reservoir and cylinder, and dissolved drug is entrained in aerosolized form in the air stream, and exits from the open end of the cylinder3 (Fig 1) . This device has been relegated to a place in history, due to its labor-intensive operation. Nevertheless, the physical principles by which it creates the aerosol are used in the jet nebulizer that uses an extrinsic gas flow through a narrow aperture (Venturi) which results in a pressure gradient entraining drug mixture from a liquid reservoir (Fig 2) . Baffles are commonly placed above the Venturi constriction to filter larger particles, preventing their entrainment in the cylinder and returning them to the liquid phase reservoir. Most jet nebulizers for ventilator circuits have small reservoirs allowing for mixing of drug in 3 to 6 ml of saline solution-these are termed small-volume nebulizers (SVN). Ultrasonic nebulizers create an aerosol above a liquid reservoir by use of a high-frequency signal, typically 1 MHz (Fig 3) .
Such devices are usually placed in various positions in the inspiratory limb of the ventilator circuit so that aerosol, once created, is entrained by a tidal breath to the patient. When jet nebulizers are used, they add an additional gas flow of 3 to 10 L/min and tidal volumes during nebulization increase by the amount required to create the aerosol. Some newer ventilators have the capacity to defer part of the tidal volume to a jet nebulizer. Thus, the precise desired tidal volume can be delivered even during nebulization therapy, and aerosol is created only during inspiration; this theoretically reduces loss of aerosol into the exhalation limb of the ventilator circuit.3
Extemal gas source 3-1 0 Ipm FIGURE 2. A common jet nebulizer system. An extrinsic gas flow, either from a compressed air source or from the ventilator passes through a Venturi and is accelerated leading to a pressure gradient that causes diluent/solubilized drug in the reservoir to be aerosolized and then entrained in another stream of gas (tidal volume) going to the patient. are affected by the volume in the reservoir,5 the position of the nebulizer in the circuit,6 the gas flow5 (in nebtilizer systemn,s), and the frequency of the ultrasonic signal3 (for ultrasonic systems). Some data sulggest that a significant amount of drug is retained on the side walls of the nebulizer.3 Furthermore, the particular design of the reservoir chamber and baffles impacts on particle sizes and retained drug so that there is considerable variability among products.7
The MDIs generally deliver particles in the 1 to 7 Am range but immediately upon actuation, MDIs create droplets that are much. larger until the diluent evaporates and droplets decrease in size to the effective MMAD size range (1 to 10 gm).' There are several mechanisms by which aerosols are delivered and deposited within the respiratory tract. We include a brief overview herein and refer the interested reader to several excellent reviews.1 8 Diffusional transport refers to the random moti.on of particles in a uniform gas of homogenous temperature in response to bombardment by gas molecules; brownian motion is a manifestation of this mechanism of particle transport. Diffusional transport is most important in the distribution of small (<0.1 ,Im) particles in distal airways.
Inertial transport refers to the motion. of particles that do not follow the stream of the inspired gas but rather impact upon conducting air-say x s . alls because of their inertial (velocity and max&ls) --.baracteristics.
The larger the particle size, the greater the contribution of this form of transport, which primarily operates on particles greater than 1 gm in. diameter.
Electrical transport refers to the propensity of electrically charged particles to deposit in airways and probably is not a major contributor to deposition in human lungs.
The 2. Gas Velocity: The velocity of inspired gas is an important determinant of particle transport and deposition. Higher inspiratory flow rates increase turbulent flow leading to impaction of particles by inertial and other forces in more proximal airways. Interestingly, low -density gases such as heliox may reduce turbulent flow and could be employed to improve delivery of therapeutic aerosols.'0 Furthermore, the transport mechanism predominating at any given airway site is dependent on airway geometry. In the upper airways, gas travels at high velocities and inertial deposition is the predominant mechanism of particle delivery. In the most distal airways, gas velocities are low, favoring gravitational and diffusional mephanisms.11
Aerosol Delivery in Mechanically Ventilated
Patients
From even a superficial overview of the principles governing aerosol transport and deposition, one might conclude that aerosol therapy during mechanical ventilatory support presents obstacles to drug delivery. Specifically, even if particle size is similar during treatment of spontaneously breathing and mechanically ventilated patients, the ventilator circuit, endotracheal tube, and ventilator-determined factors could substantially influence transport and deposition of a given agent13" 4 (Table 1) . Accordingly, we review pertinent clinical investigations of drug delivery and efficacy during mechanical ventilation in either lung models or patients. These investigations have generally attempted to quantitate drug deposition or measure a physiologic end point of drug effect.
Quantitative Studies: Conventional aerosol delivery systems deliver less aerosol in mechanically ventilated patients than in spontaneously breathing, nonintubated patients (Table 2 ). Maclntyre et al15 determined the delivery of nebulized radiolabeled penta-acetic acid in seven intubated, mechanically ventilated patients with a variety of disease processes. These particles of 1 to 5 ,um were delivered by a positive-pressure system attached to the patient's endotracheal tube. The "inspiratory pressure, sensitivity, and flow were adjusted to deliver tidal volumes similar to what the patient had been receiving on the volume ventilator," but parameters were not discussed in detail. Only 2.9 percent of the dose was actually delivered to the patients undergoing mechanical ventilation as compared with 11 percent of a nebulized dose administered to nonintubated control subjects. The authors concluded that "aerosol delivery in mechanically ventilated patients is significantly reduced and that this is probably due to a combination of suboptimal breathing pattern, intrinsic airway disease, and the endotracheal tube functioning as both a site for aerosol deposition through impaction as well as a barrier to gastrointestinal absorption."
O'Doherty et al16 studied the deposition of nebulized radioactive albumin in a ventilator-lung model. They used ventilators (Siemens Servo 900C) in volume control mode, with a heated water bath humidifier and attached the "Y', piece of the ventilator circuit to an endotracheal tube (ETT) leading to a filter that trapped nebulized drug. Three different nebulizer systems were assessed and each was tested at two different points in the ventilator circuit, placed just before the Y piece in the inspiratory limb and just after it. Flow rates of 8 L/min and 5.5 L/min, rates of between 10 and 20 bpm, and several nebulizer volumes of fill (amount of saline solution diluent) were studied. Drug delivery to the filter ranged from 3.1 to 5.4 percent of initial dose, depending on nebulizer model. Low flow rates, low respiratory rates, and higher inspiratory times improved delivery of the nebulized particles, the size of which were not measured. In addition, the greater the volume of fill of the nebulizer, the greater the aerosol delivery.
O delivery. They used a ventilator (Bear II) and four brands of nebulizer placed 30 cm from the Y piece in the inspiratory limb of the ventilator circuit. Respiratory rates of 12 and 20 bpm, flow rates of 40, 60, and 80 L/min, and volumes of fill between 2 and 6 ml were evaluated. They found that the amount of aerosol delivered varied widely (3 to 37 percent) between various brands of nebulizers. The amount of inhaled medication was proportional to the duty cycle (percentage of time spent in inspiration), so slower respiratory rates and lower flow rates improved delivery. Humidification of the inspired gas decreased delivery while endotracheal tube size did not affect delivery.
Crogan and Bishop18 delivered MDI through an adapter (Marquest) and ETT into a test lung during both continuous and pulsatile (postactuation) flows of 20 and 60 L/min. They measured drug (metaproterenol) at the end of the tube, finding that 3.0 percent of the initial dose was delivered through a size 6 mm ETT, while 6.5 percent was delivered through a 9 mm ETT; the remainder of the drug was deposited on the walls of the ETT 
to 800 ml breaths per minute with a 20 percent inspiratory time. Actuation directly into the ETT adapter was associated with delivery of 7.3 percent of drug, while actuation into the spacing device led to about 35 percent delivery regardless of position in the circuit.
Taylor and Lerman23 studied the delivery of salbutamol by MDI through 3-to 6-mm ETTs and 19-gauge intra-ETT catheters during continuous gas flows. Delivery was greatest through the intra-ETT catheter (96 percent) and ranged from 2.5 to 12.3 percent increasing with the size of the ETT. Recently, Taylor et a124 examined delivery of salbutamol by MDI through a 6-mm ETT at constant (nonpulsatile) flows of 30 L/min delivered through an ETT swivel adapter or through varying lengths and diameters of intra-ETT catheters. Delivery of MDI was 50 times higher through the intra-ETT catheters than through the standard swivel adapter. These data suggest that all of any given actuation reaches the distal ETT through 22-cm-long, 14 (Fig 4) . In addition, the measurement of intrinsic positive end-expiratory pressure (PEEP) in airflow-obstructed patients is a measure of dynamic hyperinflation, and hence, indirectly, a reflection of airway resistance. Also, some ventilators possess or may be adapted to provide measurement of airway resistance by an interruptor technique. The use of aerosol bronchodilators in intubated patients began in the 1960s. 27 Fresoli et a128 treated eight bronchospastic patients undergoing anesthesia for a variety of reasons with 0.225 to 0.375 mg of isoproterenol by MDI finding that wheezing was reduced in seven. Gold29 treated 12 anesthetized patients with 250 ,ug of isoproterenol delivered by MDI actuation into a side-port adapter with manual bag inflation, finding that peak airway pressure decreased in all 12 by between 10 and 33 mm Hg.
Sprague30 studied 16 anesthetized patients who developed bronchospasm while undergoing operative procedures finding that 680 ,tg of isoetharine per 140 ,g of phenylephrine by MDI decreased peak inspiratory pressures in all patients with a mean reduction of 3.2 cm H20.
Gay et al31 randomized 18 mechanically ventilated patients with "suspected airway obstruction" to crossover between albuterol delivered by MDI (3 puffs, 270 Ag) or nebulizer (2.5 mg). The MDI cannister and adapter were attached to a conduit with a balloon attached; actuation occurred into the reservoir balloon and was then delivered by slow manual inflation with end-inspiratory pause. Expiratory resistance was measured using an interruptor technique before and after treatments. They found that both methods of delivery significantly reduced airway resistance. The study by Fuller et al,19 cited above, examined the effect of MDI (with a spacer) and nebulizers on peak airway pressures, finding that neither significantly reduced peak pressures. MacIntyre et al15 (also cited above) showed that 1.25 mg of metaproterenol in 4 ml of normal saline solution via a nebulizer attached to the proximal ETT with flows of 8 to 10 L/min did not significantly alter pulmonary mechanics or heart rate.
Fernandez et a132 studied 20 patients who required mechanical ventilation secondary to an exacerbation of COPD. Salbutamol (0.2 mg) or ipratropium bromide (0.04 mg) was given by MDI actuation into an intraendotracheal catheter coupled to slow bag ventilation, with 10 h of washout between treatments. Airway mechanics were measured 60 min after treatments. They found that both agents decreased airway pressures and resistance when delivered by this method.
Farhangfar et a133 studied 12 patients with COPD randomized to receive two puffs of albuterol by MDI (two puffs, 180 ,ug) or jet nebulizer (2.5 mg) with a crossover to alternative delivery at 6 h. Both drug delivery systems reduced mean airway pressures as well as intrinsic PEEP and there was no statistically significant difference between the two techniques. Gutierrez and Nelson34 also studied 20 mechanically ventilated patients after delivery of 180 ,ug MDI or 2.5 mg of nebulized metaproterenol. Airway resistance was measured before and after using the "static mechanics function" on a ventilator (Puritan-Bennett 7200a). Airway resistances significantly decreased with each drug administration technique.
Hess et al35 evaluated 16 patients using a ventilator (Siemens Servo 900C) with inspiratory times of 25 percent and inspiratory pauses of 5 percent finding that both 360,g of albuterol by MDI actuated into the ETT and 2.5 mg of nebulized albuterol reduced expiratory resistive pressure compared with placebo. Bakow et a136 also observed similar results, though their methods were not well described. We recently reported a crossover study in which ten patients were randomized to receive increasing doses of either MDI (actuated into an ETT adapter) or nebulized albuterol. After 4 h, patients crossed over to the alternate method of administration. Cumulative doses of 100 puffs of MDI albuterol (9 mg) had no effect on resistive pressure, whereas cumulative doses of 2.5 and 7.5 mg of nebulized albuterol reduced resistive pressure.37 Dhand et a138 studied six mechanically ventilated patients with COPD finding that ten puffs of MDI albuterol delivered via a spacer (Aerovent) in the inspiratory limb significantly reduced resistive airway pressure.
Atropine-like drugs, including ipratropium-bromide delivered by MDI and glycopyrrolate delivered by nebulizers, are frequently used to treat airflow obstruction in nonintubated patients. Despite the fact that these agents are also widely administered to intubated, mechanically ventilated patients, only one study in adults32 (described above) has demonstrated clinical efficacy in this setting. No studies in ventilated adults have determined whether anticholinergics provide equivalent or additive effects when compared with p-agonist alone.
The assumption that bronchodilator drugs may be delivered by aerosol in intubated patients with efficacy comparable to treatment of the nonintubated patient is likely true. However, insofar as aerosol delivery is affected by the presence of an ETT and by ventilator parameters, the following questions must be answered so that such therapies may be reliably and reproducibly administered in a safe and effective manner.
Are nebulized treatments effective? If so,.what
is the optimal method of nebulization, where in the ventilator circuit should the nebulizer be placed, and how much of each drug should be administered by this method? The studies cited above that evaluated drug nebulization did not assess the utility of continuous nebulization, an approach now favored in many intensive care units. This nebulization strategy should be formally evaluated with the techniques described above. When jet nebulizers are used, what is the optimal volume of fill?
2. Are MDIs effective? If so, where in the circuit should the MDI be actuated, during what period of the respiratory cycle, and in what doses should MDI be administered? Is a spacing chamber or intra-ETT catheter required for the delivery of MDI and if so, what is its optimal design and where should it be placed in the ventilator circuit? Lastly, even if a standardized effective method of MDI administration is determined, are they "doomed to extinction"39 because they emit polluting chlorofluorocarbons? 3. What are the optimal ventilator parameters for the delivery of nebulized aerosols to intubated patients and are the same parameters optimal for MDI delivery systems? The in vitro work by O'Doherty et al16 is very important in beginning to address this issue; in vivo work should be performed to confirm their findings. 4 . Are atropine-like drugs effective? Do they add any additional benefit when added to ,32-agonists?
Are there some patients who will respond to atropinelike drugs who will not respond to 032-agonists? Are any of these questions affected by whether a patient is intubated or not?
5. Would vehicles such as heliox, which enhance the delivery of aerosols in spontaneously breathing patients,10 be useful (and feasible) for intubated, CHEST / 106 / 2 / AUGUST, 1994 567 chanically ventilated patients?
Since the delivery of these agents depends on numerous variables, studies must be performed to determine preferred, standardized methods of delivery to assure adequate safety and efficacy for the patient. We conducted an informal survey of Chicago-area teaching hospitals in September 1992, finding that both 32-agonists and atropine-like drugs are widely used both by MDI and nebulization in mechanically ventilated patients. Furthermore, some of these institutions used MDI delivery techniques that may not be effective.'9'37 In a second informal poll at the 1993 American Thoracic Society meetings, 13 of 32 physicians (10 community-based and 22 university-based) delivered aerosols by MDI through a side-port adapter, 12 used an in-line spacer for MDI, and 7 used nebulizers exclusively. Of the 25 using MDI, 8 also used nebulization for some treatments.
Therapeutic Aerosols in Pediatrics
Compared with the literature regarding adult treatment, even fewer studies have examined the efficacy of therapeutic aerosols in mechanically ventilated infants and children. Based on the adult data presented above, various ventilator parameters (small tidal volumes) and the presence of small-diameter ETTs would be expected to hamper delivery of aerosols to children. Cameron et a140 compared deposition rates of aerosolized budesonide for five jet nebulizers and an ultrasonic nebulizer in a pediatric ventilator-lung model. Deposition varied between devices from a low of 0.15 percent to a high of 1.52 percent. Arnon ventilated rabbits with an infant ventilator (Bourns LS 104T), finding that the deposition of nebulized radiolabeled particles was dependent on the brand of nebulizer used. Furthermore, the most efficient nebulizer system was a "nontraditional" device that created submicronic particles at higher than normal flow rates. However, Watterberg et al46 compared urine samples of nine infants after jet and submicronic nebulized cromolyn, finding that despite increased rates of delivery, no more cromolyn was recovered in the urine after submicronic therapy. This suggests that submicronic particles may be more likely to be exhaled.
We are aware of only one clinical study that has examined a physiologic end point after aerosol bronchodilator therapy in infants. Rio et a147 delivered isoetharine by jet nebulizer to 13 preterm infants with respiratory distress syndrome. Airway resistance decreased in all patients and lung compliance tended to increase. To our knowledge, no similar physiologic studies have been performed to determine the efficacy of MDI in ventilated infants and children. Preliminary data concerning surfactant aerosol therapy in infants with respiratory distress syndrome, presented below, examine physiologic end points for efficacy of aerosol therapy but further studies are required to determine the optimal method of delivery to this patient population.
Other Drugs Delivered by Aerosol Aerosolized steroids are commonly used in the treatment of nonintubated patients with asthma and COPD. Beclomethasone and triamcinolone are the steroids most commonly administered by aerosol. In severe acute asthma, systemic steroids are invariably used in lieu of inhaled steroids, since the aerosol delivery is likely compromised and dose requirements are likely higher. There may be critically ill patients in whom systemic steroids would be contraindicated but who would benefit from aerosolized steroids. Some in vitro data suggest that aerosolized steroids may be delivered through pediatric ETTs through an MDI spacer system.41'48 To our knowledge, no studies have evaluated aerosolized steroids in the treatment of bronchospasm in intubated patients.
Cromolyn sodium is another agent used in the outpatient management of asthma. Since cromolyn requires a significant duration of therapy before it is effective as an inhibitor of mast cell degranulation, it has not been believed to be useful in the course of critical illness.
The role of mucolytics in clinical practice is controversial. Although studies have shown that acetylcysteine, the commercially available aerosolized mucolytic, is effective in vitro in liquefying both mucoid and purulent secretions, clinical benefit of such therapy is not clear.49 This agent is used as adjunctive therapy for patients with tenacious secretions or for dissolution of bronchial plugs. One study has been performed in mechanically ventilated patients, which showed that acetylcysteine delivered by nebulizer caused bronchospasm; this study did not address its mucolytic activity.50 Therefore, there are no data (to our knowledge) to support use of this agent in mechanically ventilated patients.
Aerosolized antibiotics have been studied for the treatment and prophylaxis of infections in nonintubated patients with cystic fibrosis (gentamicin),51 HIV-related disease (pentamidine for Pneumocystis carinii pneumonia),52 and immunocompromised states (amphotericin B for fungal infections). 53 One of the main theoretic problems with such therapies is that delivery of aerosols to consolidated lung may be limited. Amphotericin B is not currently approved for aerosol therapies, although some animal data suggest that it may be effective for treatment of pulmonary fungal infections. 54 Girard et a155 examined plasma concentrations of pentamidine after ultrasonic aerosolization (4 mg/kg) in 8 intubated and 18 nonintubated patients. They found that plasma concentrations of pentamidine in intubated patients were double those of nonintubated patients and similar to levels observed after intramuscular injection of 4 mg/kg, although they did not examine actual lung deposition/delivery. Thus aerosolized pentamidine therapy for pulmonary infections in intubated patients remains experimental and must be validated in prospective trials with clinical end points. Aerosolized ribavirin has also been used for treatment of (viral) infections in intubated patients. After studies demonstrating safety, 28 infants with respiratory syncytial virus pneumonia requiring mechanical ventilation were prospectively randomized to receive 7 days of continuously nebulized ribavirin or placebo. Ribavirin decreased both days on the ventilator and days in hospital, but did not reduce overall mortality.56 To our knowledge, no similar studies have been performed in mechanically ventilated adults with viral pneumonitides.
Surfactant suspension has been delivered via ETTs in the management of infant respiratory distress syndrome and adult respiratory distress syndrome (ARDS).57 Experimental models of ARDS in animals58'59 suggested that aerosolized surfactant was at least as effective as instilled surfactant in attenuating lung injury as measured by pulmonary mechanics and oxygenation despite lower doses of drug in the lung. Reines et a160 studied 49 patients with ARDS randomized to receive saline solution nebulization, intratracheal surfactant suspension, or surfactant nebulization for 5 days. Patients receiving surfactant by either modality had improved mortality and oxygenation compared with the group receiving saline solution. Nebulized surfactant was well tolerated except for two episodes of occlusion of the expiratory filters of the ventilator circuits. Weg et al6' studied 52 patients comparing nebulized surfactant with saline solution over 5 days finding a trend toward improved survival and shunt in the surfactant-treated group. They observed filter occlusion as well, in one case leading to pneumothorax. A randomized placebocontrolled multicenter trial is currently underway to assess the effect of nebulized surfactant on the course of ARDS.
RECOMMENDATIONS
Based on this review of the literature, we suggest the following for the delivery of aerosols to intubated patients:
Which drugs? The only aerosolized medications that have been shown to be effective in intubated patients are d-agonist bronchodilators (in both adults and children) and ribavirin (in children). Use of other agents should be restricted to experimental protocols until further studies substantiate effectiveness and safety.
Which methods of delivery and how? Nebulized and MDI-delivered drugs should be titrated to physiologic effect until more conclusive studies determine standardized, reproducible methods of delivery, specifically noting the following:
(1) When MDI bronchodilators are used, the clinician should be aware that adequate medication may not be reaching the airways of the patient. Further studies, using physiologic end points, are required to determine optimal dosing through and optimal positioning of spacer devices. Based on the available data, when MDIs are used they should be administered through an in-line spacing device, following airway mechanics for effect, until further studies are performed to determine whether actuation into the ETT can deliver adequate doses of medication. The use of intra-ETT catheters appears promising, but in vivo studies are required to validate this method of MDI delivery before it can be recommended for routine use in ventilated patients.
(2) When jet nebulizers are used, we suggest using the largest possible volumes of fill. The clinician must be aware of the specifications of aerosol production for their particular ultrasonic and jet nebulizer (MMAD, optimal operating procedures).
What ventilator settings? Ventilators should be set at reduced inspiratory flows (40 to 50 L/min) and respiratory rates to maximize inspiratory time during aerosol administration. Of course, either maneuver could result in sufficient reduction of expiratory time to cause or worsen dynamic gas trapping, as indicated by the existence of intrinsic PEEP. If intrinsic PEEP exists, it should be minimized by ventilator settings that maximize expiratory time. The role of additional maneuvers, ie, the use of end-inspiratory pauses, remains to be illuminated, but it may be advisable based on the limited available data. When MDIs are used, slow bag inflation with an inspiratory pause may also be effective.
Future studies will determine the methods for maximal delivery of aerosolized medications. Yet the CHEST / 106 / 2/ AUGUST, 1994 569 multitude of patient and ventilator circuit-determined variables impacting on aerosol delivery suggest that there will be no universally applicable method of aerosol delivery or dose that serves all patients. Rather, we strongly urge that clinicians consider these factors and titrate their therapies to effect as is the practice with most other interventions in critically ill patients.
CONCLUSIONS
Aerosols have been used widely in the treatment of critically ill intubated patients. However, the data supporting the physiologic effectiveness of such therapies are currently incomplete. Instead, data from the nonintubated patient population have been used to justify similar techniques of administration to intubated patients. The use of aerosol therapies in the critical care unit has become a multimillion dollar industry precisely because aerosol therapies are potentially as useful in intubated patients as in nonintubated patients. However, further studies are required to determine the optimal mode of administration and appropriate dosing for each modality, to fully realize the potential of aerosol therapies in mechanically ventilated patients.
